NCT04741542View on ClinicalTrials.gov

Safety of SP-420 in the Treatment of Transfusional Iron Overload

PHASE1TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

March 9, 2021

Primary Completion Date

January 10, 2024

Study Completion Date

January 10, 2024

Conditions
Iron Overload
Interventions
DRUG

SP-420

This study aims to establish the safety of SP-420 administered orally three times per week (TIW).

Trial Locations (1)

78229

Mays Cancer Center, UT Health San Antonio, San Antonio

Sponsors
All Listed Sponsors
collaborator

Abfero Pharmaceuticals, Inc

INDUSTRY

lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT04741542 - Safety of SP-420 in the Treatment of Transfusional Iron Overload | Biotech Hunter | Biotech Hunter